



## SEQUENCE LISTING

<110> HARTMANN, ARNO  
BRANDT, SILKE  
RIEKE, ERWIN  
SOBEL, CORNELIUS  
LO, KIN-MING  
WAY, JEFFREY C.  
GILLIES, STEPHEN

<120> ERYTHROPOIETIN FORMS WITH IMPROVED PROPERTIES

<130> MERCK-2056

<140> 09/708,506

<141> 2000-11-09

<150> 60/164,855

<151> 1999-11-12

<160> 26

<170> PatentIn Ver. 2.1

<210> 1

<211> 514

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (8)..(505)

<223> Human EPO, DNA sequence modified but no change in  
protein sequence

<400> 1

cccgggt gcc cca cca cgc ctc atc tgt gac agc cga gtg ctg gag agg 49  
Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg  
1 5 10

D  
tac ctc ttg gag gcc aag gag gcc gag aat atc acg acc ggc tgt gct 97  
Tyr Leu Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala  
15 20 25 30

gaa cac tgc agc ttg aat gag aac atc acc gtg cct gac acc aaa gtg 145  
Glu His Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val  
35 40 45

aat ttc tat gcc tgg aag agg atg gag gtt ggc cag cag gcc gta gaa 193  
Asn Phe Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu  
50 55 60

gtg tgg cag ggc ctg gcc ctg ctg tcg gaa gct gtc ctg cgg ggc cag 241  
Val Trp Gln Gly Leu Ala Leu Ser Glu Ala Val Leu Arg Gly Gln  
65 70 75

gcc ctg ttg gtc aac tct tcc cag ccg tgg gag ccc ctg caa ctg cat 289  
Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His  
80 85 90

gtg gat aaa gcc gtg agt ggc ctt cgc agc ctc acc act ctg ctt cgg 337  
Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg  
95 100 105 110

gct ctg gga gcc cag aag gaa gcc atc tcc cct cca gat gcg gcc tca 385  
Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser

115	120	125	
gct gct ccc ctc cgc aca atc act	gct gac act ttc cgc aaa ctc ttc	433	
Ala Ala Pro Leu Arg Thr Ile Thr	Ala Asp Thr Phe Arg Lys Leu Phe		
130	135 140		
cga gtc tac tcc aat ttc ctc cgg	gga aag ctg aag ctg tac aca ggg	481	
Arg Val Tyr Ser Asn Phe Leu Arg	Gly Lys Leu Lys Leu Tyr Thr Gly		
145	150 155		
gag gcc tgc cgg aca ggg gac aga	tgactcgag	514	
Glu Ala Cys Arg Thr Gly Asp Arg			
160	165		

<210> 2  
 <211> 166  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu  
 1 5 10 15  
 Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His  
 20 25 30  
 Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe  
 35 40 45  
 Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp  
 50 55 60  
 Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu  
 65 70 75 80  
 Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp  
 85 90 95  
 Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu  
 100 105 110  
 Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala  
 115 120 125  
 Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val  
 130 135 140  
 Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala  
 145 150 155 160  
 Cys Arg Thr Gly Asp Arg  
 165

<210> 3  
 <211> 52  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 3  
 ccgggtgccc caccacgcct catctgtgac agccgagtgc tggagaggta cc

<210> 4  
<211> 49  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 4  
tcttggaggc caaggaggcc gagaatatca cgaccggctg tgctgaaca 49

<210> 5  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 5  
ctgcagcttg aatgagaaca tcaccgtgcc tgacaccaaa gtgaatttct at 52

<210> 6  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 6  
gcctggaaga ggatggaggt tggccagcag gccgtagaag tgtggcag 48

<210> 7  
<211> 51  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 7  
ggcctggccc tgctgtcgga agctgtcctg cggggccagg ccctgttggt c 51

<210> 8  
<211> 49  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 8  
aactcttccc agccgtggga gcccctgcaa ctgcatgtgg ataaagccg 49

<210> 9  
<211> 52  
<212> DNA  
<213> Artificial Sequence

D1  
Cont

<220>

<223> Description of Artificial Sequence: Primer

<400> 9

tgagtggcct tgcagcctc accactctgc ttcgggctct gggagcccag aa 52

<210> 10

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 10

ggaagccatc tcccctccag atgcggcctc agctgctccc ctccgcac 48

<210> 11

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 11

aatcactgct gacactttcc gcaaactctt ccgagtctac tccaatttcc tcc 53

<210> 12

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 12

ggggaaagct gaagctgtac acaggggagg cctgccggac aggggacaga tgactcgag 59

<210> 13

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 13

tcttggaggc caaggaggcc gaggagatca cgaccggctg tgctgaaca 49

<210> 14

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 14

ctgcagcttg aatgagcaga tcaccgtgcc tgacaccaa gtgaatttct at 52

D1  
Cont

<210> 15  
<211> 49  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 15  
cagtccttccc agccgtggga gcccctgcaa ctgcatgtgg ataaagccg

49

<210> 16  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 16  
ggaagccatc tcccctccag atgcggccgc agctgctccc ctccgcac

48

<210> 17  
<211> 232  
<212> PRT  
<213> Homo sapiens

<220>  
<223> Human IgG1 Fc region-mature protein

<400> 17  
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala  
1 5 10 15  
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro  
20 25 30  
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val  
35 40 45  
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val  
50 55 60  
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln  
65 70 75 80  
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln  
85 90 95  
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala  
100 105 110  
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro  
115 120 125  
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr  
130 135 140  
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser  
145 150 155 160  
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr

D  
cont

	165		170		175
Lys Thr Thr Pro	Pro Val Leu Asp Ser	Asp Gly Ser Phe	Phe Leu Tyr		
180	185	190			
Ser Lys Leu Thr Val Asp Lys	Ser Arg Trp Gln Gln	Gly Asn Val Phe			
195	200	205			
Ser Cys Ser Val Met His	Glu Ala Leu His Asn	His Tyr Thr Gln Lys			
210	215	220			
Ser Leu Ser Leu Ser	Pro Gly Lys				
225	230				

<210> 18  
 <211> 326  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <223> Human IgG2 constant region (CH1, hinge, CH2, Ch3) - mature protein

<400> 18  
 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg  
 1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr  
 65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys  
 85 90 95

Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro  
 100 105 110

Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp  
 115 120 125

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp  
 130 135 140

Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly  
 145 150 155 160

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn  
 165 170 175

Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp  
 180 185 190

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro  
 195 200 205

Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu  
 210 215 220

*DI*  
*Cont*

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn  
225 230 235 240

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile  
245 250 255

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr  
260 265 270

Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys  
275 280 285

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys  
290 295 300

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu  
305 310 315 320

Ser Leu Ser Pro Gly Lys  
325

<210> 19

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Linker

<400> 19

Ala Ala Ala Ala

1

<210> 20

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Linker

<400> 20

Ala Ala Ala Ala Ala

1

5

<210> 21

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Linker

<400> 21

Gly Gly Gly Gly

1

<210> 22

<211> 5

<212> PRT

<213> Artificial Sequence

DI  
Comp

<220>  
<223> Description of Artificial Sequence: Linker

<400> 22  
Gly Gly Gly Gly Gly  
1 5

<210> 23  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Linker

<400> 23  
Gly Gly Gly Gly Gly Gly  
1 5

<210> 24  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Linker

<400> 24  
Gly Gly Pro Gly Gly  
1 5

<210> 25  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Linker

*DI*  
*cont*  
<400> 25  
Gly Gly Gly Gly Ser  
1 5

<210> 26  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Linker

<220>  
<223> This linker sequence may encompass five to  
twenty five amino acids is groups of (GGGGS)

<400> 26  
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly  
1 5 10 15

Gly Gly Gly Ser Gly Gly Gly Ser  
20 25

---